The potential of PDE4 inhibitors in asthma or COPD.
D Spina - Current opinion in investigational drugs (London …, 2000 - europepmc.org
At least 11 families of distinct phosphodiesterase (PDE) isoenzymes are known to regulate
the function of many cells secondary to altering the intracellular levels of second …
the function of many cells secondary to altering the intracellular levels of second …
Phosphodiesterase 4 (PDE4) inhibitors in asthma and chronic obstructive pulmonary disease (COPD)
J Szmuszkovicz, SP Gupta, B Kundu, SK Khare… - Progress in Drug …, 1999 - Springer
Phosphodiesterases (PDE) are a family of enzymes responsible for the metabolism of the
intracellular second messengers cyclic AMP and cyclic GMP. PDE4 is a cyclic AMP specific …
intracellular second messengers cyclic AMP and cyclic GMP. PDE4 is a cyclic AMP specific …
Phosphodiesterase type 4 (PDE4) inhibition: the search for effective therapy with minimal side effects
M Yeadon, N Clarke, J Ward - New Drugs and Targets for Asthma and …, 2010 - karger.com
The concept of “second messengers” operating within cells, transducing the signals
impinging on cell membranes, became well-established from the pioneering work of …
impinging on cell membranes, became well-established from the pioneering work of …
PDE 4 inhibitors: the use of molecular cloning in the design and development of novel drugs
B Hughes, R Owens, M Perry, G Warrellow… - Drug Discovery Today, 1997 - Elsevier
Phosphodiesterase 4 (PDE 4) enzymes are the principal phosphodiesterases responsible
for the hydrolysis of cAMP in pro-inflammatory leukocytes. The functional consequences of …
for the hydrolysis of cAMP in pro-inflammatory leukocytes. The functional consequences of …
2 PDE4 inhibitors–a review of the current field
NJ Press, KH Banner - Progress in medicinal chemistry, 2009 - Elsevier
Publisher Summary This chapter focuses on phosphodiesterase-4 (PDE4) enzyme inhibitors
and their potential therapeutic utility. The chapter presents the in vitro pharmacology of …
and their potential therapeutic utility. The chapter presents the in vitro pharmacology of …
Phosphodiesterase-4 inhibitor therapy for lung diseases
Phosphodiesterases (PDEs) are a superfamily of enzymes that catalyze the breakdown of
cAMP and/or cyclic guanosine monophosphate (GMP) to their inactive form. PDE4 is the …
cAMP and/or cyclic guanosine monophosphate (GMP) to their inactive form. PDE4 is the …
PDE inhibitors currently in early clinical trials for the treatment of asthma
MG Matera, C Page, M Cazzola - Expert opinion on investigational …, 2014 - Taylor & Francis
Introduction: PDE inhibitors could be useful in the treatment of asthma because of their
bronchodilator and/or anti-inflammatory activities. Recently, some selective PDE3, PDE4 …
bronchodilator and/or anti-inflammatory activities. Recently, some selective PDE3, PDE4 …
Phosphodiesterase 4 inhibitors for the treatment of asthma
JA Karlsson, D Aldous - Expert Opinion on Therapeutic Patents, 1997 - Taylor & Francis
This paper reviews the literature on the modulation of cyclic adenosine 3′ 5′-
monophosphates (cAMP) by inhibition of phosphodiesterase 4 (PDE 4) enzyme. It highlights …
monophosphates (cAMP) by inhibition of phosphodiesterase 4 (PDE 4) enzyme. It highlights …
Phosphodiesterase 4 inhibitors
JG Montana, HJ Dyke - 2001 - Elsevier
Publisher Summary This chapter describes the various aspects of phosphodiesterase 4
(PDE4) inhibitors. PDE4 is the predominant isozyme present in inflammatory cells and …
(PDE4) inhibitors. PDE4 is the predominant isozyme present in inflammatory cells and …
The therapeutic potential of PDE4 inhibitors
HJ Dyke, JG Montana - Expert opinion on investigational drugs, 1999 - Taylor & Francis
Phosphodiesterase enzymes are responsible for the inactivation of cyclic adenosine
monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). Phosphodiesterase …
monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). Phosphodiesterase …